When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
DBVT - What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
DBV Technologies S.A.
Aimmune Therapeutics(NASDAQ: AIMT) won approval from the U.S. Food and Drug Administration for its first drug -- and there are two more important firsts.
Aimmune's Palforzia is the first approved drug to treat peanut allergies, and the first approved treatment for any kind of food allergy, giving it a home run that the company, patients, and investors can all celebrate. Since Aimmune's pipeline is all about treating food allergies, this approval may be viewed as a positive sign showing the company's method can deliver.